Avanzanite Expands into Spain and Appoints María Baquerizo as Country Manager

Avanzanite Expands into Spain and Appoints María Baquerizo as Country Manager

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into Spain and the appointment of María Baquerizo López-Quectuy as Spain Country Manager. This follows a €32 million Series A investment by MVM Partners announced in November 2025 and the recent entry to France. Avanzanite’s continues to build its integrated European platform designed to accelerate access to innovative therapies for people living with rare diseases.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608541655/en/ María Baquerizo López-Quectuy, Country Manager, Avanzanite Spain

“Spain is an essential part of Avanzanite’s European vision,” said Adam Plich, Co-Founder and CEO, Avanzanite Bioscience. “The country combines scientific excellence, a sophisticated healthcare ecosystem and a large community of patients living with rare diseases who continue to face challenges accessing innovative therapies. While we are already active in Spain through our partnership with a Spanish innovator*, Maria’s appointment and growth of the team mark the next step in building a long-term presence in the country. I am excited to welcome Maria who will apply her leadership and wide-ranging experience to establishing a dedicated local presence. This demonstrates our commitment to investing in Spain and partnering closely with decision makers across the healthcare system to ultimately ensure no patient is forgotten.”